S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:PROF

Profound Medical (PROF) Stock Price, News & Analysis

$8.53
+0.25 (+3.02%)
(As of 03/28/2024 ET)
Today's Range
$8.20
$8.53
50-Day Range
$8.01
$9.46
52-Week Range
$7.11
$15.49
Volume
17,226 shs
Average Volume
44,261 shs
Market Capitalization
$208.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.58

Profound Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
71.0% Upside
$14.58 Price Target
Short Interest
Healthy
1.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of Profound Medical in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.17) to ($1.04) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

Medical Sector

620th out of 939 stocks

Surgical & Medical Instruments Industry

66th out of 97 stocks

PROF stock logo

About Profound Medical Stock (NASDAQ:PROF)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

PROF Stock Price History

PROF Stock News Headlines

Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Profound Medical (NASDAQ:PROF) Shares Down 0.1%
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Profound Medical Corp PRN
Profound Medical: Q4 Earnings Insights
Profound Medical earnings preview: what to expect
See More Headlines
Receive PROF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/29/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PROF
Employees
131
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.58
High Stock Price Target
$20.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+71.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-28,570,000.00
Net Margins
-396.85%
Pretax Margin
-398.62%

Debt

Sales & Book Value

Annual Sales
$7.20 million
Book Value
$1.28 per share

Miscellaneous

Free Float
24,058,000
Market Cap
$208.39 million
Optionable
Optionable
Beta
0.82
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Arun Swarup Menawat MBA (Age 69)
    Ph.D., Chairman of the Board & CEO
    Comp: $551.88k
  • Mr. Rashed Dewan (Age 56)
    Chief Financial Officer
    Comp: $250.37k
  • Dr. Mathieu Burtnyk (Age 42)
    Chief Operating Officer
    Comp: $246.1k
  • Mr. Hartmut Warnken (Age 51)
    Chief Commercial Officer of Outside US
    Comp: $224.93k
  • Mr. Abbey Goodman (Age 41)
    Chief Commercial Officer of US
    Comp: $353.75k
  • Mr. Stephen Kilmer
    Investor Relations
  • Mr. Jacques F. Cornet (Age 68)
    Senior VP & Product Leader Sonalleve
  • Mr. Matthew Sobczyk C.A.
    CPA, Assistant Corporate Controller
  • Mr. Levant Tinaz
    Software Developer

PROF Stock Analysis - Frequently Asked Questions

Should I buy or sell Profound Medical stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Profound Medical in the last twelve months. There are currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PROF shares.
View PROF analyst ratings
or view top-rated stocks.

What is Profound Medical's stock price target for 2024?

3 Wall Street research analysts have issued 12-month target prices for Profound Medical's shares. Their PROF share price targets range from $11.00 to $20.00. On average, they anticipate the company's stock price to reach $14.58 in the next twelve months. This suggests a possible upside of 71.0% from the stock's current price.
View analysts price targets for PROF
or view top-rated stocks among Wall Street analysts.

How have PROF shares performed in 2024?

Profound Medical's stock was trading at $8.49 at the beginning of 2024. Since then, PROF shares have increased by 0.5% and is now trading at $8.53.
View the best growth stocks for 2024 here
.

When is Profound Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PROF earnings forecast
.

How were Profound Medical's earnings last quarter?

Profound Medical Corp. (NASDAQ:PROF) announced its earnings results on Thursday, November, 4th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.03. The business earned $2.54 million during the quarter, compared to analyst estimates of $4 million. Profound Medical had a negative trailing twelve-month return on equity of 70.18% and a negative net margin of 396.85%. During the same period last year, the firm earned ($0.32) earnings per share.

What guidance has Profound Medical issued on next quarter's earnings?

Profound Medical updated its fourth quarter 2023 earnings guidance on Wednesday, January, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.9 million-$2.0 million, compared to the consensus revenue estimate of $2.0 million.

Who are Profound Medical's major shareholders?

Profound Medical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Letko Brosseau & Associates Inc. (4.82%), AIGH Capital Management LLC (2.65%), Raymond James Financial Services Advisors Inc. (2.59%), Timelo Investment Management Inc. (2.50%), Royal Bank of Canada (1.64%) and Worth Venture Partners LLC (0.66%).

How do I buy shares of Profound Medical?

Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PROF) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners